15th EADO Congress
Paris, France | April 24-27, 2019 | Maison de la Chimie

Final Programme

WWW.EADOPARIS2019.COM
Welcome Message 3
Committees 4
Scientific Programme
  Schedule at a glance 6
  Wednesday 24th April 10
  Thursday 25th April 13
  Friday 26th April 21
  Saturday 27th April 31
  Poster communications 33
General information 45
Practical Information & Venue Floor Plan 54
Sponsors & Exhibition
  Main sponsors 58
  Industry satellite symposia 59
  Exhibition Floor Plan & List of Exhibitors 63
  Exhibitors Details 64

Go to www.eadoparis2019.com to get the latest information, view the programme, abstracts, floor plan,..
Dear Colleagues,

I am pleased to welcome you to the 15th European Association of Dermato-Oncology Congress, to be held in Paris, France, from April 24 to 27, 2019.

The EADO Congress is a unique opportunity to attend lectures provided by worldwide recognised experts in the field of melanoma and skin cancers. The upmost research developments as well as clinical datas will be covered by this outstanding and innovative programme structured around plenary lectures and breakout sessions.

Around 1000 dermato-oncologists, surgeons, radiotherapists, anatomopathologists, researchers and industry professionals will attend this not-to-be-missed event in the field of Dermato-Oncology. Mutli-disciplinarity and interactions will be in the core of the Congress.

The beautiful city of Paris will undoubtedly attract delegates from all over the world, and allows us to anticipate a successful Congress. Paris is the city of love, inspiration, art and fashion. It is a wonderful combination of historic, modern, romantic, intellectual, grandiose and elegantly understated. The nightlife and warm atmosphere are welcoming and will make you feel at home.

Welcome to Paris and I hope this Congress will be a successful one!

Pr Céleste LEBBÉ
EADO 2019
Congress Chairman
COMMITTEES

Faculty Committee

Céleste LEBBÉ, Congress Chair
Martine BAGOT
Bastian BORIS
Véronique DEL MARMOL
Brigitte DRÉNO
Ana-Maria FORSEA
Claus GARBE
Jean-Jacques GROB
Georgina LONG
Josep MALVEHY
Grant McARTHUR
Ketty PERIS
Caroline ROBERT
Dirk SCHADENDORF
Alexander STRATIGOS

Scientific Committee

Nicole BASSET-SEGUIN
Maude BEZIER
Charlotte BRUGIERE
Nicolas DUPIN
Stéphane DALLE
Damien GIACCHERO
Emmanuella GUENOVA
Florian HERMS
Thomas JOUARY
Pauline LALY
Céleste LEBBÉ
Thierry LESIMPLE
Eve MAUBEC
Nicolas MEYER
Laurent MORTIER
Marie-Aleth RICHARD
Jennifer ROUX
Dimitrios SGOUROS
Pauline TETU
Local Organising Committee

Céleste LEBBÉ
Clara ALLAYOUS

EADO Executive Board

President: Claus GARBE, Tuebingen, Germany
Vice-President: Alexander STRATIGOS, Athens, Greece
Treasurer: Axel HAUSCHILD, Kiel, Germany
General Secretary: Ketty PERIS, Roma, Italy
Secretary for members: Josep MALVEHY, Barcelona, Spain
Secretary for European integration: Anna-Maria FORSEA, Bucharest, Romania
Past President: Jean-Jacques GROB, Marseille, France
Past President: Hubert PEHAMBERGER, Vienna, Austria
## SCHEDULE AT A GLANCE

### WEDNESDAY 24\(^{\text{th}}\) APRIL 2019

<table>
<thead>
<tr>
<th>TIME</th>
<th>AMPHITHEATRE LAVOISIER</th>
<th>PETIT AMPHITHEATRE</th>
<th>SALLE 151</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td>SCOPE Meeting</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Controversies in Dermato-oncology 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Controversies in Dermato-oncology 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Satellite Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td>Opening keynote lectures I</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>WELCOME RECEPTION</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>All registered participants are welcome</td>
<td>Exhibition Area</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>AMPHITHEATRE LAVOISIER</td>
<td>PETIT AMPHITHEATRE</td>
<td>SALLE 151</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>08:30</td>
<td>Management of advanced melanoma</td>
<td>Rare skin cancers and borderline neoplasms such as MELTUMP, clinic-pathological approach</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>How to prevent Melanoma Progression in tumor-free patients of...</td>
<td></td>
<td>Lymphoma</td>
</tr>
<tr>
<td>09:30</td>
<td>Trends in skin cancer epidemiology</td>
<td>Biomarkers in melanoma</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>How to prevent Melanoma Progression in tumor-free patients of...</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Trends in skin cancer epidemiology</td>
<td>Biomarkers in melanoma</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary keynote lectures II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Satellite Symposium</td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Prevention and skin cancer screening</td>
<td>Free communications 1</td>
<td>Actinic keratosis and field cancerisation</td>
</tr>
<tr>
<td>15:00</td>
<td>Satellite Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Satellite Symposium</td>
<td></td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:30</td>
<td>Non-surgical local tumor treatment: act locally, but think distant</td>
<td>Free communications 2</td>
<td>Brain metastases</td>
</tr>
<tr>
<td>18:00</td>
<td>Satellite Symposium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY 26TH APRIL 2019

<table>
<thead>
<tr>
<th>AMPHITHEATRE LAVOISIER</th>
<th>PETIT AMPHITHEATRE</th>
<th>SALLE 151</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30</strong></td>
<td>Neoadjuvant therapy</td>
<td><strong>08:30</strong></td>
</tr>
<tr>
<td><strong>09:30</strong></td>
<td>Developing a skin cancer center: what do we additionally achieve?</td>
<td><strong>09:30</strong></td>
</tr>
<tr>
<td><strong>09:30</strong></td>
<td>Practical tips for your surgical work</td>
<td><strong>10:30</strong></td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td>Management of advanced BCC and SCC</td>
<td><strong>11:00</strong></td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td>Coffee break</td>
<td><strong>11:00</strong></td>
</tr>
<tr>
<td><strong>11:00</strong></td>
<td>New therapeutic targets in melanoma</td>
<td><strong>12:00</strong></td>
</tr>
<tr>
<td><strong>12:00</strong></td>
<td><strong>Satellite Symposium</strong></td>
<td><strong>13:00</strong></td>
</tr>
<tr>
<td><strong>13:00</strong></td>
<td><strong>Satellite Symposium</strong></td>
<td><strong>14:00</strong></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td>What is new in melanoma biology</td>
<td><strong>15:30</strong></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td>Best posters session</td>
<td><strong>16:30</strong></td>
</tr>
<tr>
<td><strong>15:30</strong></td>
<td>Coffee break</td>
<td><strong>16:30</strong></td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td>Coffee break</td>
<td><strong>17:00</strong></td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td>What is new in NMSC biology</td>
<td><strong>18:00</strong></td>
</tr>
<tr>
<td><strong>18:00</strong></td>
<td>Free communications 3</td>
<td><strong>18:00</strong></td>
</tr>
<tr>
<td></td>
<td>Genodermatoses and associated cancers</td>
<td><strong>18:30</strong></td>
</tr>
</tbody>
</table>
### SATURDAY 27TH APRIL 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Amphitheatre Lavoisier</th>
<th>Petit Amphitheatre</th>
<th>Salle 151</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Cases: management of difficult to treat carcinomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td>Dermoscopy and confocal microscopy cases (1)</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td>Dermoscopy and confocal microscopy cases (2)</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Plenary keynote lectures IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Closing Ceremony and Awards</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SCOPE (SKIN CARE IN ORGAN TRANSPLANT PATIENTS, EUROPE) MEETING

WORKSHOP
09:00 - 12:30 | PETIT AMPHITHEATRE - Level 0
Chair: Deniz SECKIN (Turkey)

- Welcome and introduction
  Deniz SECKIN (Turkey)

- Melanoma in the context of organ transplantation: current issues and future outlooks
  Christoph HOELLER (Austria), Alexandra GEUSAU (Austria)

- Challenges for immunotherapy of Merkel cell carcinoma in organ transplant patients (including Q&A)
  Jürgen BECKER (Germany)

- Posttransplant Merkel cell carcinoma: what are the challenges and what does the SCOPE experience tell us?
  Carla FERRÁNDIZ-PULIDO (Spain)

- Tumor board: Case 1, Case 2 and Case 3
  Coffee break

- Management of the posttransplant advanced and high-stage cutaneous SCC: What are the difficulties, challenges and solutions? (including Q&A)
  Chrysalyne SCHMULTS (United States)

- Closing remarks and future perspectives
  Charlotte PROBY (United Kingdom)
CONTROVERSIES IN DERMATO-ONCOLOGY 1

WORKSHOP
13:30 - 14:45 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Céleste LEBBÉ (France), Claus GARBE (Germany), Jean-Jacques GROB (France)

- Prevention campaign will prevent skin cancer - Yes
  Alexander STRATIGOS (Greece)
- Prevention campaign will prevent skin cancer - No
  Claus GARBE (Germany)
- Will lymph node surgery remain a main therapy in melanoma? - Yes
  David MORENO-RAMIREZ (Spain)
- Will lymph node surgery remain a main therapy in melanoma? - No
  Axel HAUSCHILD (Germany)
- Adjuvant therapy should be moved to primary melanoma stage II - Yes
  Jean-Jacques GROB (France)
- Adjuvant therapy should be moved to primary melanoma stage II - No
  Paul LORIGAN (United Kingdom)

CONTROVERSIES IN DERMATO-ONCOLOGY 2

WORKSHOP
14:45 - 16:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Brigitte DRÉNO (France), Ketty PERIS (Italy), Alexander STRATIGOS (Greece)

- We should routinely measure quality of life of advanced melanoma patients - Yes
  Jessica HASSEL (Germany)
- We should routinely measure quality of life of advanced melanoma patients - No
  Isabelle BORGET (France)
- Tumor mutational burden (TMB) will guide our future systemic treatments - Yes
  Selma UGUREL (Germany)
- Tumor mutational burden (TMB) will guide our future systemic treatments - No
  Olivier MICHIELIN (Switzerland)
- Treatment of advanced melanoma: combining or sequencing? - Combining
  Céleste LEBBÉ (France)
- Treatment of advanced melanoma: combining or sequencing? - Sequencing
  Dirk SCHADENDORF (Germany)
## OPENING CEREMONY

**PLENARY SESSION**  
**17:30 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1**

- Welcome address  
  Céleste LEBBÉ (France),  
  Claus GARBE (Germany)
- New developments in occupational skin cancer: WHO disease burden project and implications for our patients  
  Swen Malte JOHN (Germany)

## KEYNOTE LECTURES 1

**PLENARY SESSION**  
**18:00 - 19:00 | AMPHITHEATRE LAVOISIER - Level 1**  
**Chairs:** Céleste LEBBÉ (France), Claus GARBE (Germany), Caroline ROBERT (France)

- The long journey from melanocyte to melanoma  
  *Boris BASTIAN (United States)*
- Targeting innate immunity in cancer treatment  
  *Eric VIVIER (France)*
- Raising the efficacy in immunotherapy of melanoma: what are we going to achieve?  
  *Jennifer WARGO (United States)*
MANAGEMENT OF ADVANCED MELANOMA

WORKSHOP
08:30 - 09:30 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Paolo ASCIERTO (Italy), Thomas GAJEWSKI (United States), Caroline ROBERT (France)

- Combining or sequencing targeted therapy and immunotherapy
  Paolo ASCIERTO (Italy)
- How to overcome primary and secondary resistance to immune checkpoint inhibitor
  Thomas GAJEWSKI (United States)
- How should we evaluate our patients in the era of immunotherapy?
  irRECIST, irRC, iRECIST?
  Caroline ROBERT (France)

RARE SKIN CANCERS AND BORDERLINE NEOPLASMS SUCH AS MELTUMP, CLINIC-PATHOLOGICAL APPROACH

WORKSHOP
08:30 - 10:30 | PETIT AMPHITHEATRE - Level 0
Chairs: Petr ARENBERGER (Czech Republic), Boris BASTIAN (United States), Maxime BATTISTELLA (France), Matilda BYLAITE-BUCINSKIENE (Lithuania), Arnaud DE LA FOUCHARDIERE (France), Judit OLAH (Hungary)

- Adnexal Tumors
  Maxime BATTISTELLA (France)
- MELTUMP
  Arnaud DE LA FOUCHARDIERE (France)
- Neoplastic disorders of the nipple
  Erika VARGA (Hungary)
- Borderline vascular tumors
  Matilda BYLAITE-BUCINSKIENE (Lithuania)
- Soft tissue tumors
  Judit OLAH (Hungary)
- Overview on rare skin tumors
  Petr ARENBERGER (Czech Republic)
### LYMPHOMA WORKSHOP
#### 09:00 - 10:30 | ROOM 151 - Level 1
**Chairs:** Martine BAGOT (France), Julia SCARISBRICK (United Kingdom), Rudolf STADLER (Germany)

- **Tumor clone frequency is a robust predictor of progression and survival in patients with early stage mycosis fungoides**
  *Adèle DE MASSON (France)*

- **International landscape of therapies in CTCL, Results of the PROCLIPI Study**
  *Pietro QUAGLINO (Italy)*

- **Therapeutic Strategies for improved management in CTCL**
  *Rudolf STADLER (Germany)*

- **New monoclonal antibodies for the treatment of CTCL**
  *Martine BAGOT (France)*

- **Clinical endpoints updates and considerations for future staging**
  *Julia SCARISBRICK (United Kingdom)*

- **Management of Cutaneous B cell lymphoma**
  *Antonio COZZIO (Switzerland)*

### HOW TO PREVENT MELANOMA PROGRESSION IN TUMOR-FREE PATIENTS OF...
#### WORKSHOP
#### 09:30 - 10:30 | AMPHITHEATRE LAVOISIER - Level 1
**Chairs:** Axel HAUSCHILD (Germany), Jean-Jacques GROB (France), Nicolas MEYER (France)

- **Stage II**
  *Jean-Jacques GROB (France)*

- **Stage III**
  *Axel HAUSCHILD (Germany)*

- **Stage IV**
  *Nicolas MEYER (France)*

---

14
TRENDS IN SKIN CANCER EPIDEMIOLOGY

WORKSHOP
11:00 - 12:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Sara GANDINI (Italy), Claus GARBE (Germany), David WHITEMAN (Australia)

- Incidence of melanoma in Europe 1950 - 2030
  Claus GARBE (Germany)
- Which percentage of melanoma is caused by UV radiation, and what proportion could be prevented?
  David WHITEMAN (Australia)
- Nevi and melanoma: who, when and how?
  Sara GANDINI (Italy)
- What do we achieve with screening examinations?
  Andreas STANG (Germany)

BIOMARKERS IN MELANOMA

WORKSHOP
11:00 - 12:00 | PETIT AMPHITHEATRE - Level 1
Chairs: John HAANEN (Netherlands), Olivier MICHELIN (Switzerland), Selma UGUREL (Germany)

- Biomarkers in melanoma, an overview
  Olivier MICHELIN (Switzerland)
- Circulating cytokines and immune related toxicity
  Jenny LEE (Austria)
- Microbiome
  Beth HELMINK (United States)
- Single cell RNA seq of immune infiltrates
  Krisztian HOMICSKO (Switzerland)
CASES OF ADVERSE EVENTS IN IMMUNO-ONCOLOGY

WORKSHOP
11:00 - 12:00 | ROOM 151 - Level 1
Chairs: Barouyr BAROUDJIAN (France), Lucie HEINZERLING (Germany), Christoph HOELLER (Austria)

- A case of Myositis
  Lucie HEINZERLING (Germany)
- Myocarditis: what clinicians should know
  Dimitri ARANGALAGE (France)
- An unusual Hematologic side effect
  Erwin STRASSER (Germany)
- Immune related hepatitis: can we resume the treatment?
  Olivier ROUX (France)
- Beware of rare endocrinologic immune related adverse events
  Florence BRUNET-POSSENTI (France)

KEYNOTE LECTURES 2

PLENARY SESSION
12:00 - 13:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Céleste LEBBE (France), Alexander STRATIGOS (Greece)

- Where and when will melanoma incidence decrease?
  David WHITEMAN (Australia)
- How to modulate tumor microenvironment?
  Thomas GAJEWSKI (United States)
- Molecular resistance to targeted therapy, from bench to bedside
  Grant MCARTHUR (Australia)
PREVENTION AND SKIN CANCER SCREENING

WORKSHOP
14:00 - 15:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Véronique DEL MARMOL (Belgium), Ana Maria FORSEA (Romania), Eduardo NAGORE (Spain)

- UVR and cellular damage: implications for skin cancer prevention
  Amaya VIROS (United Kingdom)
- Melanoma risk and sunbeds use – time to close the debate
  Mariano SUPPA (Belgium)
- Prevention according to different clinical profile
  Eduardo NAGORE (Spain)
- Skin cancer Chemoprevention - current evidence
  Ana Maria FORSEA (Romania)

ACTINIC KERATOSIS AND FIELD CANCERISATION

WORKSHOP
14:00 - 15:00 | ROOM 151 - Level 1
Chairs: Ketty PERIS (Italy), Eggert STOCKFLETH (Germany), Nicole KELLENERS-SMEETS (Netherlands)

- Biology of AK
  Eggert STOCKFLETH (Germany)
- Diagnosis of AK
  Caterina LONGO (Italy)
- Field directed treatments
  Nicole KELLENERS-SMEETS (Netherlands)
- AK treatment in organ transplant recipients
  Ketty PERIS (Italy)
FREE COMMUNICATIONS 1: MELANOMA TREATMENT

FREE COMMUNICATIONS
14:00 - 15:00 | PETIT AMPHITHEATRE - Level 0
Chairs: Sophie DALAC-RAT (France), Lionel LARUE (France), Charlotte PROBY (United Kingdom), Dimitris SGOUROS (Greece), Damien GIACCHERO (France)

FC02 | Safety & efficacy of cryopreserved autologous tumor infiltrating lymphocytes (LN-144, lifileucel) in previously treated metastatic melanoma patients

FC03 | Response rates with talimogene laherparepvec monotherapy in patients with stage IIIB-IVM1C melanoma previously treated with a checkpoint inhibitor
Gogas H.*, Gutzmer R., Malvehy J., Mehnert J. M., Liu C., Pickett C., Snyder W., Chesney J. (Greece)

FC04 | Redirected T-cell mediated lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings

FC06 | Prediction of irAEs in ipilimumab-treated melanoma patients based on serum autoantibodies

FC07 | Update of survival and cost of metastatic melanoma with new drugs: estimations from the melbase cohort

FC08 | Tace for patients with metastatic melanoma in the liver
Martynkov D.*, Kosyrev V., Nazarova V. (Russian Federation)

FC05 | Real world evidence in advanced melanoma from a national, non-interventional study of nivolumab monotherapy or in combination with ipilimumab (NICO)

FC01 | Real-world evidence of the effectiveness of cobimetinib combined with vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma
NON-SURGICAL LOCAL TUMOR TREATMENT: ACT LOCALLY, BUT THINK DISTANT

WORKSHOP
16:30 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Christoph HOELLER (Austria), Ricardo VIEIRA (Portugal), Philippe SAIAG (France)

• Radiotherapy
  Philippe SAIAG (France)
• Intrallesional injections
  Christoph HOELLER (Austria)
• Other local treatments
  Ricardo VIEIRA (Portugal)

BRAIN METASTASES

WORKSHOP
16:30 - 18:00 | ROOM 151 - Level 1
Chairs: Emilie LE RHUN (France), Friedegund MEIER (Germany), Hussein TAWBI (United States)

• Diagnosis and local treatment of CNS metastasis: surgery and radiotherapy
  Michael WELLER (Switzerland)
• Targeted therapy alone or in combination with RT in melanoma CNS metastases
  Friedegund MEIER (Germany)
• Immunotherapy alone or in combination with RT in melanoma CNS metastases
  Hussein TAWBI (United States)
• Challenges in the design of CNS metastases trials
  Emilie LE RHUN (France)

FREE COMMUNICATIONS 2: CARCINOMA

FREE COMMUNICATIONS
16:30 - 18:00 | PETIT AMPHITHEATRE - Level 0
Chairs: Stéphane DALLE (France), Helen GOGAS (Greece), Janice MEHNERT (United States)

FC09 | Follow-up of patients with complete remission of locally advanced basal-cell carcinoma after vismodegib discontinuation: French study of 119 patients
FC17 | Prognostic subgroups in stage T3-AJCC8 for cutaneous squamous cell carcinoma: tentative T3 stage subclassification
Conde-Ferreirós A., Corchete-Sánchez L. A., Puebla-Tornero L., Román-Curto C., Cañueto J.* (Spain)

FC11 | Cemiplimab in patients with advanced cutaneous squamous cell carcinoma: clinical experience from the phase 1 and phase 2 studies

FC10 | Cemiplimab for the treatment of metastatic and locally advanced cutaneous squamous cell carcinoma: prospective study in a French onco-dermatology unit
Herms F.*, Delyon J., Baroudjian B., De Masson A., Lebbé C., Basset-Seguin N. (France)

FC15 | Opportunities for improving the efficiency of keratinocyte cancer care in primary and specialist care: population-based dutch cohort studies
Wakkee M., van Egmond S., Bindels P., van der Lei J., Louwman M., Nijsten T., Hollstein L.* (Netherlands)

FC12 | Synergistic targeting of PI3K-MTOR and MAPK pathwas in Merkel cell carcinoma
Temblador A.*, Topalis D., Andrei G., Snoeck R. (Belgium)

FC13 | Phase II study of KX2-391 ointment 1%, a novel field treatment based on src/tubulin polymerisation inhibition, for actinic keratosis

FC14 | Long-term clinical benefit to anti-CCR4 mogamulizumab: post-hoc results from mavoric, a phase 3 study in previously treated cutaneous t-cell lymphoma

FC16 | Outcome after treatment for sebaceous carcinoma: a multicenter study

Thuret A.*, Ménard C., Léon C., Richard J.-B., Jestin C., de Maria F. (France)

FC19 | Trends of sunbed use and in characteristics, knowledge, attitude and behavior in 15-75 aged French sunbed users: baromètre cancer, 2010-2015
Thuret A.*, Ménard C., Léon C., Richard J.-B., Jestin C., de Maria F. (France)
FRIDAY 26TH APRIL 2019

NEOADJUVANT THERAPY

WORKSHOP
08:30 - 09:30 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Christian BLANK (Netherlands), James LARKIN (United Kingdom), Peter MOHR (Germany)

• Neoadjuvant immunotherapy in melanoma
  Christian BLANK (Netherlands)
• Neoadjuvant targeted therapy in melanoma
  Peter MOHR (Germany)
• Neoadjuvant therapy and lessons from other tumor types and lessons to learn from former neoadjuvant trials in melanoma
  James LARKIN (United Kingdom)

DERMOSCOPY AND CONFOCAL MICROSCOPY

WORKSHOP
08:30 - 09:30 | ROOM 151 - Level 1
Chairs: Luc THOMAS (France), Iris ZALAUBEK (Austria), Caterina LONGO (Italy)

• How dermoscopy improves differential diagnosis of melanoma
  Luc THOMAS (France)
• How confocal microscopy improves management decisions
  Caterina LONGO (Italy)
• When instruments are not enough, clinical clues are needed
  Aimilios LALLAS (Greece)
• Questions & Answers
DEVELOPING A SKIN CANCER CENTER: WHAT DO WE ADDITIONALLY ACHIEVE?

WORKSHOP
08:30 - 10:30 | PETIT AMPHITHEATRE - Level 0
Chairs: Claus GARBE (Germany), Lidija KANDOLF-SEKULOVIC (Serbia and Montenegro), Dirk SCHADENDORF (Germany), Lise BOUSSEMART (France)

- The optimal melanoma care pathway - the European perspective
  Lidija KANDOLF-SEKULOVIC (Serbia and Montenegro)
- The system of quality assurance of skin cancer centers in Germany
  Claus GARBE (Germany)
- Biobanking in skin cancer centers
  Dirk SCHADENDORF (Germany)
- Translational research in a skin cancer center: when advances in next generation sequencing serve melanoma patients’ care
  Lise BOUSSEMART (France)
- E-health data and their role in skin cancer patient management
  Stine LUTZE (Germany)
- Discussion

PRACTICAL TIPS FOR YOUR SURGICAL WORK

WORKSHOP
09:30 - 10:30 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Florence CORGIBET (France), Roland KAUFMANN (Germany), Vernon SONDAK (United States)

- Before and after surgical procedures
  Florence CORGIBET (France)
- Surgical procedures for the primary tumour
  Roland KAUFMANN (Germany)
- About the sentinel node biopsies and nodal dissections
  Vernon SONDAK (United States)
NEW TECHNOLOGIES FOR THE DIAGNOSIS OF SKIN CANCER: FROM COMPUTER VISION (AUTOMATIZED DIAGNOSIS) TO INNOVATION IN PHOTONICS

WORKSHOP
09:30 - 10:30 | ROOM 151 - Level 1
Chair: Véronique DEL MARMOL (Belgium), Josep MALVEHY (Spain), Nesrine BRAHIMI (France)

- High definition Ultrasound and skin cancer diagnosis approach
  Philippe BAHADORAN (France)
- LC OCT: A new definition for Optical coherence tomography to diagnose skin cancer
  Mariano SUPPA (Belgium)
- Early skin cancer detection and follow up using polarized dynamic speckle
  Xavier ORLIK (France)
- Ex vivo confocal microscopy a new approach for skin cancer margins
  Josep MALVEHY (Spain)

MANAGEMENT OF ADVANCED BCC AND SCC

WORKSHOP
10:30 - 12:00 | PETIT AMPHITHEATRE - Level 0
Chairs: Nicole BASSET-SEGUIN (France), Ulrike LEITER (Germany), Michael MIGDEN (United States)

- General principles of management of NMSC
  Alexander STRATIGOS (Greece)
- Surgery in advanced tumors (SCC and BCC)
  David MORENO-RAMIREZ (Spain)
- Systemic treatment of advanced BCC
  Nicole BASSET-SEGUIN (France)
- Systemic Treatment of advanced SCC
  Ulrike LEITER (Germany)
- Expert Panel discussion
  David MORENO-RAMIREZ (Spain), Nicole BASSET-SEGUIN (France), Ulrike LEITER (Germany), Alexander STRATIGOS (Greece), Ingrid WOLF (Austria)
- Expert panel discussion: Difficult to treat BCC- challenging cases
  Matilda BYLAITE-BUCINSKIENE (Lithuania)
- Expert panel discussion: Difficult to treat SCC- challenging cases
  Ingrid WOLF (Austria)
NEW THERAPEUTIC TARGETS IN MELANOMA

WORKSHOP
11:00 - 12:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Brigitte DRÉNO (France), Grant MCARTHUR (Australia), Jessica HASSEL (Germany)

- Targeted therapies in BRAF mutated advanced melanoma: beyond BRAF and MEK combinations
  Grant MCARTHUR (Australia)
- Targeted therapies in NRAS mutated melanoma, what can we expect?
  Amelie BOESPFLUG (France)
- The future of immuno combination therapies in advanced melanoma
  Brigitte DRÉNO (France)
- cKIT: still a relevant target?
  Julie DELYON (France)

UPDATE ON THE SKIN CANCERS IN IMMUNOSUPPRESSED PATIENTS, ON BEHALF OF SCOPE

WORKSHOP
11:00 - 12:00 | ROOM 151 - Level 1
Chairs: Emilie DUCROUX (France), Catherine HARWOOD (United Kingdom), Deniz SECKIN (Turkey)

- Introduction
  Deniz SECKIN (Turkey)
- What is new in the pathogenesis and treatment of posttransplant Kaposi’s sarcoma?
  Stéphane BARETE (France)
- The role and therapeutic implications of HPV presence in posttransplant squamous cell carcinoma: SCOPE research update
  Jan Nico BOUWES-BAVINCK (Netherlands)
- Skin field cancerization: Converging transcription/epigenetic regulatory pathways of translational value
  Paolo DOTTO (Switzerland)
KEYNOTE LECTURES 3

PLENARY SESSION
12:00 - 13:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Céleste LEBBÉ (France), Jürgen BECKER (Germany)

- Biology and therapy of Merkel cell carcinoma
  Paul NGHIEM (United States)
- Targeting pathways in basal cell carcinoma: sonic hedgehog and beyond
  Nicole BASSET-SEGUIN (France)

WHAT IS NEW IN MELANOMA BIOLOGY?

WORKSHOP
14:00 - 15:30 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Boris BASTIAN (United States), Nicolas DUMAZ (France),
        Amaya VIROS (United Kingdom)

- Nongenetic mechanisms as drivers of tumor evolution and therapy resistance
  Jean-Christophe MARINE (Belgium)
- TERT promoter mutations, telomere length and melanoma survival and risk
  Rajive KUMAR (Germany)
- Novel roles of ROCK-Myosin II in melanoma
  Victoria SANZ-MORENO (United Kingdom)
- Neural Crest Stemness in Melanoma
  Lukas SOMMER (Switzerland)

VIRUS INDUCED CANCER

WORKSHOP
14:00 - 15:30 | ROOM 151 - Level 1
Chairs: Jürgen BECKER (Germany), Nicolas DUPIN (France),
        Paul NGHIEM (United States)

- Immunobiology of Merkel cell carcinoma
  Jürgen BECKER (Germany)
- Progress and challenges in Merkel cell carcinoma management
  Paul NGHIEM (United States)
- Update on oncogenesis and therapy for Kaposi’s sarcoma
  Nicolas DUPIN (France)
### BEST POSTERS SESSION

#### FREE COMMUNICATIONS

**14:00 - 15:30 | PETIT AMPHITHEATRE - Level 0**

**Chairs:** Ralf GUTZMER (Germany), Gaëlle QUEREUX (France), Henri MONTAUDIE (France), Emmanuella GUENOVA (Switzerland)

| **P003** | Usefulness of the “two-step method” of digital follow-up in early stage melanoma detection in at high risk French patients - a retrospective study  
Gasparini G., Madjlessi N., Delyon J., Carmisciano L., Brahimi N., Bagot M., Basset-Seguin N., Battistella M., Lebbé C., Hermès F., Baroudjian B.* (France) |
| **P004** | Association between breslow thickness and dermoscopic findings in melanoma  
| **P018** | A study on confidence in classification of skin lesions by deep neural networks  
| **P001** | Genomic aberrations may predict positive sentinel lymph node biopsy in melanoma of young adults  
Ma S.*, Vivar K., Sondak V., Messina J. (United States) |
| **P002** | Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma  
| **P006** | Development and validation of a nomogram to assess sentinel node biopsy positivity in melanoma patients  
Bertolli E.*, Calsavara V. F., Macedo M. P. D., Pinto C. A. L., Duprat Neto J. P. (Brazil) |
| **P005** | Whole-body MRI including diffusion weighted imaging for the surveillance of melanoma patients at high risk for recurrence  
Jansen Y. J. L.*, Inneke W., Brussaard C., Neyns B. (Belgium) |
| **P008** | Clinical significance of braf/nras concurrent mutations in a clinic-based metastatic melanoma cohort  
| **P010** | Molecular genetic testing of ocular melanoma (uveal and conjunctival melanoma)  
Nazarova V.*, Orlova K., Natalia M., Utyashev I., Demidov L. (Russian Federation) |
P007 | Epidemiological study of adjuvant treatments from the French national melanoma database RIC-MEL

P009 | MIR-193A as therapeutic agent in cutaneous melanoma
Carpi S.*, Polini B., Romanini A., Nieri P. (Italy)

P011 | Response to chemotherapy after immunotherapy in 19 advanced melanoma patients

P015 | Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases

P012 | The importance of pharmacists for dabrafenib and trametinib use in real-life: analysis of data from pharmaceutical consultations since 2016
Davoine C.*, Cartier F., Toulemonde-Deldicque A., Laly P., Lebbé C., Baroudjian B., Delyon J., Madelaine I. (France)

P013 | Severe Gastrointestinal toxicity of MEK inhibitors: a 5-year monocentric experience

P014 | Immune-related hepatitis: clinical aspect and proposed management

P016 | Improving patient experience of immunotherapy treatment for melanoma: the leeds nurse-led immunotherapy telephone clinic
Marples M.*, Jackson H., Nicholson H., Ryder B., Ingham K., Hook J. (United Kingdom)

P017 | Cutaneous eruption as a prognosis indicator for cancer patients treated with EGFR tyrosine kinase inhibitors: a meta-analysis
Wang Y.*, Wu J., Chung W. (United States)
WHAT IS NEW IN NMSC BIOLOGY?

WORKSHOP
17:00 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Irene LEIGH (United Kingdom), Dany NASSAR (France), Chrysalyne SCHMULTS (United States)

• Mechanisms of Resistance to Hedgehog/Smootherned Inhibitors in BCC
  Mike MIGDEN (United States)
• Regulation of Epithelial Mesenchymal Transition in SCC
  Dany NASSAR (France)
• Squamous Carcinogenesis: Commonalities and Difference Across Epithelial Cell Types
  Catherine HARWOOD (United Kingdom)
• Molecular Prediction of Recurrence and Metastasis in SCC
  Chrysalyne SCHMULTS (United States)

GENODERMATOSES AND ASSOCIATED CANCERS

WORKSHOP
17:00 - 18:00 | ROOM 151 - Level 1
Chairs: Susanna PUIG (Spain), Pierre VABRES (France), Pierre WOLKENSTEIN (France)

• Genetics of basal cell carcinoma
  Sergey NIKOLAEV (France)
• Genetics of familial melanoma
  Susanna PUIG (Spain)
• Neurofibromatosis 1 and related tumours
  Pierre WOLKENSTEIN (France)
• Genetic disorders of the PIK3CA/PTEN/MTOR pathway
  Pierre VABRES (France)
FREE COMMUNICATIONS 3: MELANOMA BIOMARKERS, DIAGNOSTIC

FREE COMMUNICATIONS
17:00 - 18:30 | PETIT AMPHITHEATRE - Level 0

Chairs: Véronique BATAILLE [United Kingdom], Julie DELYON [France], Caroline GAUDY [France], Emmanuella GUENOVA [Switzerland]

FC22 | Clinical and dermoscopic features of thin nodular melanoma: a study of the international dermoscopy society

FC23 | Computer-aided classifier with a deep convolutional neural network surpasses board-certified dermatologists in skin tumor diagnosis
Fujisawa Y.*, Otomo Y., Ogata Y., Nakamura Y., Fujimoto M. (Japan)

FC20 | MC1R gene variants and melanoma risk according to histological type, body site, and breslow thickness: a pooled analysis from the M-SKIP project

FC26 | Multiple primary cutaneous melanoma: incidence, time to subsequent melanomas, differences in staging and survival

FC24 | Sex differences in genetic modulation of melanoma-specific and disease-free survival

FC30 | Clinicopathological factors associated with mortality of thin (≤1.00mm) cutaneous melanoma

FC25 | Inhibition of EMMPRIN/VEGFR-2 interaction decreases malignant phenotype of melanoma models

FC27 | Circulating PD-L1 expressing cytotoxic T cells are correlated with a negative immune climate and are prognostic in melanoma
Meireson A.*, Kruse V., Chevolet I., Sundahl N., Ost P., Brochez L. (Belgium)
**FC28** | Ambra1 and loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanoma

**FC29** | A targeted mRNA analysis predicts survival of metastatic melanoma patients under braf inhibitors
SATURDAY 27TH APRIL 2019

DERMOSCOPY AND CONFOCAL MICROSCOPY CASES (1)

WORKSHOP
08:30 - 09:30 | ROOM 151 - Level 1
Chair: Philippe BAHADORAN (France), Josep MALVEHY (Spain), Dimitris SGOUROS (Greece)

- Equivocal hypomelanotic lesion or regressive lesion (melanoma vs nevus); Difficult BCC; Lichen planus like keratosis simulating melanoma in dermoscopy
  Caterina LONGO (Italy)
- Vulvar melanosis vs MM; Nail melanonychia (melanoma vs benign lesion); melanoma during vemurafenib or immunotherapy treatment
  Mona AMINI-ADLER (France)
- Basal cell carcinoma (dermoscopy, OCT and confocal), squamous cell carcinoma (Bowen), melanoma vs nevus
  Mariano SUPPA (Belgium)
- Early LMM (diagnosis, margins, management, recurrences,..); Benign equivocal flat pigmented lesion on the face; Case of ex-vivo confocal in Mohs surgery (multimodal)
  Susanna PUIG (Spain)

CASES: MANAGEMENT OF DIFFICULT TO TREAT CARCINOMAS

WORKSHOP
08:30 - 11:00 | AMPHITHEATRE LAVOISIER - Level 1
Chairs: Jean-Jacques GROB (France), Eve MAUBEC (France), Chrysalyne SCHMULTS (United States), Victor FARRICHA (Portugal)

- Advanced SCC arising in hidradenitis suppurativa
  Eve MAUBEC (France)
- Multiple scalp SCCs in a patient with chronic lymphocytic leukemia
  Chrysalyne SCHMULTS (United States)
- Rapid growth of SCC while on JAK inhibitor for myelofibrosis
  Victor FARRICHA (Portugal)
- What is a difficult to treat BCC?
  Jean-Jacques GROB (France)
- A young patient with sarcoidosis and voriconazole-induced locally advanced SCC
  Eve MAUBEC (France)
- A renal transplant patient with multiply recurrent SCC. Is anti PD-1 treatment ever appropriate in transplant patients?
  Chrysalyne SCHMULTS (United States)
## DERMOSCOPY AND CONFOCAL MICROSCOPY CASES (2)

**WORKSHOP**

<table>
<thead>
<tr>
<th>09:30 - 10:30</th>
<th>ROOM 151 - Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairs:</strong> Harald KITTLER (Austria), Aimilios LALLAS (Greece), Iris ZALAUBEK (Austria)</td>
<td></td>
</tr>
</tbody>
</table>

- When dermoscopy is straight forward  
  **Aimilios LALLAS (Greece)**
- When dermoscopy is not straight forward  
  **Harald KITTLER (Austria)**
- When confocal is of help  
  **Caterina LONGO (Italy)**
- Pre-and intra-operative use of non-invasive techniques  
  **Susanna PUIG (Spain)**

## KEYNOTE LECTURES 4

**PLENARY SESSION**

<table>
<thead>
<tr>
<th>11:30 - 12:30</th>
<th>AMPHITHEATRE LAVOISIER - Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairs:</strong> Céleste LEBBÉ (France), Véronique DEL MARMOL (France)</td>
<td></td>
</tr>
</tbody>
</table>

- What’s new in non melanoma skin cancer?  
  **Brigitte DRÉNO (France)**
- What’s new in melanoma?  
  **Olivier MICHELIN (Switzerland)**
- What’s new in cutaneous lymphoma?  
  **Marie BEYLOT-BARRY (France)**

## CLOSING CEREMONY & AWARDS

**PLENARY SESSION**

<table>
<thead>
<tr>
<th>12:30 - 13:00</th>
<th>AMPHITHEATRE LAVOISIER - Level 1</th>
</tr>
</thead>
</table>

## CME CREDITS

An accreditation of the 15th EADO Congress for the Continuing Medical Education was asked to the European Union of Medical Specialists (UEMS).

More information on credits will be posted on the Congress website.
P001 | Genomic aberrations may predict positive sentinel lymph node biopsy in melanoma of young adults  
Ma S.*, Vivar K., Sondak V., Messina J. (United States)

P002 | Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma  

P003 | Usefulness of the “two-step method” of digital follow-up in early stage melanoma detection in at high risk French patients - a retrospective study  
Gasparini G., Madjlessi N., Delyon J., Carmisciano L., Brahimi N., Bagot M., Basset-Seguin N., Battistella M., Lebbé C., Hermès F., Baroudjian B.* (France)

P004 | Association between breslow thickness and dermoscopic findings in melanoma  

P005 | Whole-body MRI including diffusion weighted imaging for the surveillance of melanoma patients at high risk for recurrence  
Jansen Y. J. L.*, Inneke W., Brussaard C., Neyns B. (Belgium)

P006 | Development and validation of a nomogram to assess sentinel node biopsy positivity in melanoma patients  
Bertolli E.*, Calsavara V. F., Macedo M. P. D., Pinto C. A. L., Duprat Neto J. P. (Brazil)

P007 | Epidemiological study of adjuvant treatments from the French national melanoma database RIC-MEL  

P008 | Clinical significance of braf/nras concurrent mutations in a clinic-based metastatic melanoma cohort  

P009 | MIR-193A as therapeutic agent in cutaneous melanoma  
Carpi S.*, Polini B., Romanini A., Nieri P. (Italy)

P010 | Molecular genetic testing of ocular melanoma (uveal and conjunctival melanoma)  
Nazarova V.*, Orlova K., Natalia M., Utyashev I., Demidov L. (Russian Federation)
P011 | Response to chemotherapy after immunotherapy in 19 advanced melanoma patients

P012 | The importance of pharmacists for dabrafenib and trametinib use in real-life: analysis of data from pharmaceutical consultations since 2016
Davoine C.*, Cartier F., Toulemonde-Deldicque A., Laly P., Lebbé C., Baroudjian B., Delyon J., Madelaine I. (France)

P013 | Severe Gastrointestinal toxicity of MEK inhibitors: a 5-year monocentric experience

P014 | Immune-related hepatitis: clinical aspect and proposed management

P015 | Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases

P016 | Improving patient experience of immunotherapy treatment for melanoma: the leeds nurse-led immunotherapy telephone clinic
Marples M.*, Jackson H., Nicholson H., Ryder B., Ingham K., Hook J. (United Kingdom)

P017 | Cutaneous eruption as a prognosis indicator for cancer patients treated with EGFR tyrosine kinase inhibitors: a meta-analysis
Wang Y.*, Wu J., Chung W. (United States)

P018 | A study on confidence in classification of skin lesions by deep neural networks
DIAGNOSIS AND STAGING OF MELANOMA

P019 | Diagnostics of skin melanoma and changes in benign nevi during pregnancy (in pregnant women) based on optical and digital dermoscopy in Belarus
Prakoshyn A.*, Aliaksandr Z., Lud N. (Belarus)

P020 | Primary cutaneous melanoma with microsatellite metastases presenting as an amelanotic nodule on the ear

P021 | High level of the cytokine P-STAT5 in locally invasive cutaneous melanoma tissue is protective of melanoma-specific death
Chong S., Rowe C., Claeson M.*, Malt M., Smithers B. M., Green A. C., Khosrotehrani K. (Australia)

P022 | Liquid biopsy melanoma: MCAM and ABCB5 enrichment and molecular biomarkers characterization allow to define high-risk disease progression phenotype
Rapanotti M. C.*, Suarez Viguria T. M., Campione E., Giulia S., Galeota M., Rossi P., Bernardini S., Luca B. (Italy)

P023 | Accuracy assessment of a real-time skin cancer diagnostic device based on laser spectroscopy and deep learning algorithm using aesthetic lasers
Pyun S. H.*, Munavalli G., Goo B., Min W. (United States)

P024 | Intraoperative portable large field of view gamma camera improves node detection in patients with melanoma undergoing sentinel lymph node biopsy
Kozlov A.*, Hall N., Terando A. (United States)

P025 | Ex vivo dermoscopy with derm dotting and targeted sectioning in pigmented skin lesions: better diagnosis in less time
Haspeslagh M.*, Clauwaert V., Taildeman J., Facchetti F., Brochez L. (Belgium)

P026 | Trends in sentinel lymph node biopsy enactment for cutaneous melanoma in the Netherlands: more performed, lower yield

P027 | A pediatric case of a difficult melanocytic lesion
Iuliana Elena N.*, Cristina Mihaela C., Sinziana D., Ana Maria P., Doru C., Irina M. (Romania)

P028 | The DERMSCAN project: development of a new type of digital dermatoscope for diagnosis and follow-up of skin cancer
Mylle S.*, Garmyn M., De Smedt J., Janssen L., Boone M., Bonny M., Suys E., Maes N., van Kelst S., Verhaeghe E., Brochez L. (Belgium)
P029 | Sentinel node biopsy for malignant melanoma - a new service in Northern Ireland
Croitoru C.*, Nelson A., Diggin P. (United Kingdom)

P030 | Amelanotic acral melanoma mimicking a plantar wart
Gasparini G., Cioni M.*, Cozzani E., Parodi A. (Italy)

EPIDEMIOLOGY AND PREVENTION OF SKIN CANCER

P031 | The incidence of various types of skin tumors in patients without complaints of tumors in primary care dermatology
Vertieva E., Allenova A.*, Lepekhova A., Teplyuk N., Olisova O. (Russian Federation)

P032 | Missed opportunities for melanoma detection in secondary care
Quinlan C.*, McCracken S., Tierney E., Heffron C., Fitzgibbon J., Murphy C., Bourke J. F., Murphy M. (Ireland)

P033 | Early access dermatology consultation for suspicious skin lesions as a new way for early detection of skin cancer in the general population
Mylle S.*, Hoorens I., Verhaeghe E., Brochez L. (Belgium)

P034 | Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology in UK: new insights for an accurate estimation
D’Agostino P.*, Kent A., Sharp E., Schmidt F., Turini M. (Switzerland)

P035 | Factors influencing early detection of nodular melanoma
Baltas E.*, Kovacs N., Csanyi I., Ócsai H., Kemeny L., Olah J. (Hungary)

P036 | Phase I study of KX2-391 ointment 1%, a novel field treatment based on src/tubulin polymerisation inhibition in subjects with actinic keratosis
Jarratt M.*, Wang H., Cutler D., Fang J., Kwan R. (United States)

P037 | Histological details of basal cell carcinoma in reflectance confocal microscopy
Pogorzelska-Antkowiak A.*, Antkowiak L., Antkowiak R. (Poland)

P038 | Study of skin neoplasms in a university hospital: integration of anatomopathological records and its interface with the literature
Rezende H. D., Dos Santos De Araujo A. G.*, De Almeida L. M., De Almeida A. P. M., Nahn Junior E. P., Miotto J. B. D. M. (Brazil)

P039 | Neglected giant basal cell carcinoma: low mortality, but high morbidly in a case report
Dos Santos De Araujo A. G.*, Nahn Junior E. P., Rezende H. D., De Almeida L. M., De Almeida A. P. M., Miotto J. B. D. M. (Brazil)
GENETICS AND BIOLOGY OF MELANOMA

P042 | A case of 4 synchronous cutaneous melanomas: genotype, phenotype or lifestyle? 
Gasparini G.*, Cioni M., Ciccarese G., Cozzani E., Bruno W., Parodi A. (Italy)

P043 | The role of microRNAs in multiple primary cutaneous melanomas 
Dika E.*, Lambertini M., Patrizi A., Broseghini E., Porcellini E., Riefolo M., Baraldi C., Ferracin M. (Italy)

MELANOMA / SKIN CANCER CENTER

P044 | App-based monitoring of patients with metastatic malignant melanoma under ongoing system therapy 
Lutze S., Arnold A.*, Berndt R.-D., Juenger M. (Germany)

P045 | Secondary primary non-melanoma tumors in patients with primary and metastatic cutaneous melanoma 

P046 | Real world evidence data of stage III and IV melanoma with focus on adjuvant patients within a 4-week period at German skin cancer centers 

P047 | Ear reconstruction with autologous cartilage in patient with auricular melanoma malignum after partial resection 
Gavrilova I. I.*, Firmin F. (Bulgaria)

P048 | Melanocytic proliferations of the central nervous system: a spectrum to be known 
P049 | Epidemiological characteristics and survival of a cohort patients with cutaneous melanoma in Montevideo, Uruguay in the period 2008-2017
Amarillo D.*, De Boni D., Schiavonne A., Brayer C., Giachero V., Palacios C., Tambasco C., Nantes F., Krygier G. (Uruguay)

MELANOMA PRECURSORS AND CARCINOGENESIS

P050 | Two different tumours - melanoma and SCC on the burn scar
Petrovic-Popovic D. Z.*, Novakovic M., Jeremic J., Jovic M., Bojicic B. (Serbia)

P114 | Nevus-associated melanoma of thin nodular versus superficial spreading histological subtype

MELANOMA TREATMENT

P051 | Lichenoid reaction in a patient with metastatic melanoma under pembrolizumab
Gomes N.*, Esteves M., Antunes I., Marques A., Azevedo F. (Portugal)

P052 | Bullous lichen planus after imiquimod and nivolumab
Costedoat I.*, Douset L., Gerard E., Prey S., Dutriaux C., Beylot-Barry M., Pham-Ledard A. (France)

P053 | Describe III update: a retrospective analysis of dabrafenib and/or dabrafenib + trametinib in patients with metastatic melanoma

P054 | Influence of fixed-dose nivolumab on thyroid function due to usage change
T-type calcium channel blockade impairs migration/invasion of BRAFV600E vemurafenib resistant melanoma cells depending on PTEN status
Sisó P., Barceló C., Maiques O., Soria X., Matias-Guiu X., Marti R. M.*, Macià A. (Spain)

Bilayered, non-cross-linked collagen matrix for regeneration of facial defects after skin cancer removal
Ghanaati S.* (Germany)

Cold plasma as a new treatment option in dermatologic oncology
Daeschlein G.*, Arnold A., Hillmann A., Sicher C., von Podewils S., Jünger M. (Germany)

Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
Nakamura Y.*, Fujimoto M., Fujisawa Y. (Japan)

Evaluation of anti-tumoral response after discontinuation of anti-PD1 immunotherapy in patients with metastatic melanoma

Nivolumab and ipilimumab – multiple immune-mediated adverse events and a complete response: a single case report
Ressler J.*, Höller C. (Austria)

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients treated with ipilimumab for metastatic melanoma
Gérard E.*, Leroy V., Dutriaux C., Prey S., Mertens C., Beylot-Barry M., Pham-Ledard A. (France)

Efficacy of imatinib on two mutated mucosal melanomas CKIT
Marcaillou M.*, Bedane C., Prud’homme R. (France)

Isolated limb perfusion in patients with limb melanoma. The experience of single institute
Petrochenko N.*, Rybaya O., Kharatishvili T. (Russian Federation)

Safety of target therapy and immunotherapy for metastatic melanoma in pediatric population: a rare case of advanced juvenile melanoma
Zottarelli F.*, Roberto G., Gironi L. C., Farinelli P., Sponghini A. P., Rondonotti D., Savoia P. (Italy)

Immunotherapy in melanoma – the importance of early recognition of its side effects
Martins C. A.*, Rato M. (Portugal)

Management of system therapy of metastatic malignant melanoma considering secondary malignancies
Arnold A.*, Lutze S., Jünger M. (Germany)
P067 | Hematological side effects of immune checkpoint inhibitors
Strasser E.*, Hackstein H., Heinzerling L. (Germany)

P068 | Limb preservation with isolated limb infusion for locally advanced cutaneous melanoma
Teras J.*, Teras M. (Estonia)

P115 | KEYNOTE-716: phase 3 study of adjuvant pembrolizumab (pembro) vs placebo (PBO) in resected high-risk stage II melanoma

NON-MELANOMA SKIN CANCER

P069 | Advanced squamous cell carcinoma on pembrolizumab: failure and new considerations

P070 | Merkel cell carcinoma and chronic lymphocytic leukaemia: case series and literature review
Strzałka A.*, Nejc D., Jeziorski A. (Poland)

P071 | Mechanobiology-based prediction of invasiveness of non-melanoma skin tumors
Kortam S., Merkher Y., Kramer A., Metanes I., Ad-El D., Har-shai Y., Weihs D.* (Israel)

P072 | Mogamulizumab efficacy by prior systemic therapy in patients previously treated for cutaneous T-cell lymphoma: a mavoric post-hoc analysis

P073 | Patterns of perineural invasion and prognosis in cutaneous squamous cell carcinoma. A multicenter, retrospective cohort study

P074 | Survival in a UK cohort of patients with stage III and IV Merkel cell carcinoma before the availability of first line immunotherapy
Hamada M.*, Nathan P. (United Kingdom)
Resminostat for treatment of patients with advanced stage MF or SS that have achieved disease control with systemic therapy – the Resmain study
Stadler R.*, Scarisbrick J., Knobler R., Quaglino P., Borgmann M., Orlovius M., Krauss B., Reimann P., Danhauser-Riedl S. (Germany)

Dermal invasion and lymph node status predict survival and postoperative relapse in extramammary paget’s disease: a role of sentinel lymph node biopsy
Endo Y.*, Kabashima K. (Japan)

Efficacy of electrochemotherapy versus combination vismodegib and photodynamic therapy in patients with multiple basal cell carcinomas
Goldust M.* (Iran, Islamic Republic Of)

Comparison of tumor interstitial fluid-extraction methods for proteome analysis in cutaneous squamous cell carcinoma

Development of an organotypic epithelial raft culture model of Merkel cell carcinoma
Temblador A.*, Topalis D., Andrei G., Snoeck R. (Belgium)

Fibroepithelioma of pinkus reloaded. An immunohistochemical study with stem cell markers: case series of 15 cases
Alegría Landa V.*, Mendoza Cembranos M. D., Santonja C., Kutzner H., Requena L. (Spain)

Incidence and recurrence of dermatofibrosarcoma protuberans in the Netherlands between 1989-2016
Lee L. V., Kan W., Gran S., Mooyaart A., Mureau M., Williams H., Matin R., van den Bos R., Hollestein L.* (Netherlands)

Cutaneous squamous cell carcinoma: clinical and epidemiological aspects among the population of Ukraine
Oshyvalova O.* (Ukraine)

Gorlin-Goltz syndrome in young patients: an often-missed diagnosis

Rapidly growing eccrine porocarcinoma of the leg. Does a sun-exposure have a role?
Javor S.*, Antonelli C. T., Cabiddu F. (Italy)

Spontaneous regression in Merkel cell carcinoma. Case report

A case of penile metastasis from advanced renal cell carcinoma
Hashimoto Y.*, Mitsui A., Miyake A., Oka K., Horita A., Saito I., Ohmatsu H. (Japan)

ALK expression in Merkel cell carcinoma in 232 cases
Mendoza-Cembranos M. D.*, Alegría-Landa V., Santonja C., Piris M. Á., Requena L., Kutzner H. (Spain)
P089 | Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma
Cozzani R.*, del Aguila R., Carrizo M., Sanchez S., Gonzalez A. (Argentina)

P090 | Accuracy of ultra-high-frequency ultrasound imaging to measure basal cell carcinoma thickness: a pilot study

P091 | Nicotine patch and basal cell carcinoma. Possible cause of skin cancer
Teras M.*, Teras J. (Estonia)

P092 | Cutaneous malignant chondroid syringoma with nodal relapse: a case report and literature review

P093 | A review on laser therapy for basal cell carcinoma
Kash N., Silapunt S.* (United States)

P094 | Dermoscopy of unusual case of a giant pigmented Bowen disease

P095 | Widely spread unilateral inflammatory linear verrucous epidermal nevus
Khalidi M.*, Hjira N., Boui M. (Morocco)

P097 | Highly aggressive squamous cell carcinoma: a case report
Paunescu A.-M.*, Beiu C., Nitu I. E., Sandru F. (Romania)

P098 | A historical case of a giant Marjolin ulcer on old burn scar
Elgaitibi F. A.*, Hassam B., Ismaili N., L. Benzekri, Senouci K. (Morocco)

P099 | Squamous cell carcinoma over lower limb in an Indian patient with disseminated discoid lupus erythematosus
Bhargava S.*, Kumar U., Varma K. (India)

P100 | Merkel cell carcinoma of the buttock: a case report and review
Khalidi M.*, Hjira N., Boui M. (Morocco)

P101 | DNA methylation of tumor suppressor gene p15INK4B in non-melanoma skin cancer in renal transplant recipients compared to non-transplant patients
OTHERS

P102 | Frailty screening in dermato-oncology practice; a modified Delphi study
van Winden M. E. C.*, Garcovich S., Peris K., de Jong E. M. G. J., Hamaker M. E.,
vан de Kerkhof P. C. M., Lubeek S. F. K. (Netherlands)

P103 | Descriptive study of spontaneous nevus involution in a series of 74
patients with atypical nevus syndrome under siascopy digital follow-up
Moreno S., Maiques O., Gatius S., Vea A., Barrera J., Barcelo C., Santacana M.,
Soria X., Matias-Guiu X., Marti R. M.* (Spain)

P104 | Percutaneous hepatic perfusion with melphalan using the Delcath
system’s GEN2 hemofiltration system in patients with ocular melanoma liver
metastases
Meijer T. S.*, Burgmans M. C., de Leede E. M., de Geus-Oei L.-F., Boekestijn B.,
Meer R. W., Sitzen E. M., Speetjens F. M., Tijl F. G., Kapiteijn E., Vahrmeijer A. L.
(Netherlands)

P105 | Quality of life assessment in French patients with metastatic melanoma
in real life
Kandel M.*, Allayous C., Bardet A., Dalle S., Mortier L., Dutriaux C., Guillot B.,
Leccia M.-T., Dalac S., Legoupil D., Saiag P., Montaudie H., Arnault J.-P., Brunet-
Possenti F., Grob J.-J., de Quatrebarbes J., Beylot-Barry M., Lesimple T., Aubin
F., Maubec E., Granel-Brocard F., Stoebner P.-E., Dupuy A., Dréno B., Michiels S.,
Lebbé C., Borget I. (France)

P106 | Importance of color consistency in digital dermoscopy
Diricx B., Vermeir T., Van Hoey G., Kimpe T.* (Belgium)

P107 | Papuloerythroderma of Ofuji as a clinical manifestation of primary
Sézary syndrome in a patient of mediterranean origin
Papadavid E., Diakomopoulos A.*, Kokkalis G., Karali V. (Greece)

P108 | Effect of a dermoscopy training course on the ability of dermatologists
to diagnose skin lesions
Oh H.*, Park J. H., Moon H. R. (Korea, Republic Of)

P109 | Bourneville-prise disease: the misleading acne!!
Khalidi M.*, Hjira N., Boui M. (Morocco)

P110 | Oncological implications of biological therapies, with specific focus on
skin cancer
Ócsai H.*, Kesztthelyi P., Baltás E., Oláh J., Kovács L., Kesztthelyi P., Kemény L.
(Hungary)

P111 | Nevoid basal cell carcinoma syndrome - case report
Tsekova N.*, Kirov K., Gavrilova I. (Bulgaria)
P112 | A rare case of pseudoepitheliomatous keratotic and micaceous balanitis successfully treated with 5-fluoro uracil
Bhargava S.* (India)

P113 | Different access to clinical trials for melanoma patients in Western and Eastern Europe
Östafiichuk V.*, Kukushkina M., Kukushkina S., Korovin S., Diedkov S., Chornenkyi D., Boychuk S. (Ukraine)
GENERAL INFORMATION

Organizer

EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research.

The EADO has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of Dermato-Oncology.

The EADO provides leadership by formulating and disseminating quality standards and guidelines for diagnosis and treatment of skin cancer.

The EADO provides direction, coordination and organisations of clinical, therapeutical and experimental trials in the area of skin cancer.

The EADO supports and organises meetings dedicated to the presentation of new research findings, exchange of information and education for its members in the field of Dermato-Oncology.

The EADO offers coordination and support of projects of the respective national skin cancer groups.

www.eado.org
Perspectives on Melanoma: Present Challenges and Future Considerations

Thursday, 25 April 2019 | 13:00-14:00
Amphithéâtre Lavoisier
Maison de la Chimie
Paris, France

13:00–13:05 Welcome and Introduction
Caroline Robert

Peter Mohr

13:15–13:30 Sequencing Strategies in Melanoma
James Larkin

13:30–13:55 Immuno-Oncology in Melanoma: An Interactive Discussion
Moderator: Caroline Robert

13:55–14:00 Summary and Close
Caroline Robert

This Industry-Sponsored Symposium Is Organized and Funded by Bristol-Myers Squibb.
WHEN YOU KNOW WHAT YOU’RE UP AGAINST
YOU CAN ATTACK IT

When you see a BRAF mutation, treat your patients early with the proven and durable efficacy of TAFINLAR + MEKINIST.¹²

References:
ABOUT PARIS

The most visited tourist destination in the world, with over 45 million visitors annually, it is easy to see in Paris the city of love, or the city of lights. As the capital of France, Paris’ transport system is clean, efficient and most importantly affordable. Other parts of the country are accessible from Paris in only a few hours, which makes for a large choice of day trips should you feel the need to escape the city.

SOME LESS KNOWN INTERESTING FACTS ABOUT PARIS:

• The city that has seen 4 revolutions (to date), 18 kings named Louis and at least 2 occupying forces.
• There are 65 films (and counting) that star the Eiffel Tower as a significant feature.
• Of Paris’ 2-million-strong population, around 20% are immigrants from all over the world making Paris one of the biggest multi-cultural centers in Europe.
• In the world of fashion, Paris is the only city to present haute couture shows.
• The French army is the only one in Europe that still has carrier pigeons in its ranks.
• Paris is #1 in the world when it comes to the number of libraries; it has 830 of them in total.
• With 302 stations, the Paris Métro is the 4th largest public transport system in the world.
• There are ten Statues of Liberty in France, five of which are in Paris.
• The Roman numerals on the pavement of the Place de la Concorde are the numbers of a giant sundial, and the shadow of the obelisk functions to give the time.
• Visitors to the Eiffel Tower have to climb 1,665 steps to reach the top – unless they take the elevator!

MORE INFORMATION ABOUT PARIS  WWW.PARISINFO.COM
**WORKING HOURS**

- **Banks:** approximately 08.30-12.30 / 13.45-17.00
- **Pharmacies:** approximately 08.00-19.00
- **Shops:** approximately 10.00-19.00
- **Shopping malls:** approximately 08.30-20.00
- **Embassies:** approximately 09.30-17.00

**CURRENCY**

- **France’s currency:** Euro (€).
  Currencies can be exchanged at the airport and in banks.

**ELECTRICITY NETWORK**

- France has a voltage of 220 V.

**USEFUL TELEPHONE NUMBERS**

- **Emergency Phone Number:** 112 (from a cell phone)
- **Paris Airports:** +33 1 70 36 39 50
- **Gare du Nord train station:** 3635 (for French lines only)

**TAXI**

- **Taxi G7:** +33 (0) 1 47 39 47 39 - **Alpha Taxis:** +33 (0) 1 45 85 85 85
This session will feature an interactive expert panel providing an outlook on the current perspective on immunotherapy in the management of advanced cutaneous squamous cell carcinoma (CSCC) linking the application of the most recent, relevant evidence to real patient cases.
BRAFTOVI™ in combination with MEKTOVI™ is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.¹,²

NOW APPROVED IN THE EU*  
Visit the Pierre Fabre Booth to know more about BRAFTOVI + MEKTOVI

Detailed information on this medicinal products are available on the website of the European Medicines Agency. For complete information, please refer to:

1. BRAFTOVI Summary of Product Characteristics

2. MEKTOVI Summary of Product Characteristics

*BRAFTOVI + MEKTOVI have been approved by the European Commission (EC) on the 20th September 2018. © 2019 Pierre Fabre. All rights reserved. BRAFTOVI™ is a trademark of Array BioPharma Inc. in the United States and various other countries. MEKTOVI™ is a trademark of Array BioPharma Inc. in the United States and various other countries.
CONGRESS VENUE

The 15th EADO Congress will be held from Wednesday 24th April to Saturday 27th April 2019 at the Maison de la Chimie, Paris, France.

Maison de la Chimie - 28 rue Saint-Dominique  75007 Paris

An historical, prestigious place in the heart of the 7th arrondissement, the Maison de la Chimie provides visitors with a modern house and a genuine soul. A unique place with different sides to it, combining the charm of the 18th century with the simplicity of the 1930s, the Maison de la Chimie is definitely an important Congress and conference centre in France.

OFFICIAL LANGUAGE

Organized by an International Scientific Society, all presentations will be given in English. Simultaneous interpretation will not be provided.

CONGRESS SECRETARIAT

EADO 2019 / MCI France
25 rue Anatole France - CS70139 - 92532 Levallois-Perret Cedex, France
Tel: +33 (0)1 70 39 35 54 - Fax: +33 (0)1 53 85 82 83

• General information: info@eadoparis2019.com
• Exhibition, sponsorship and advertising sales: partnership@eadoparis2019.com
• Registration & Accommodation: registration@eadoparis2019.com
• Abstracts: scientific@eadoparis2019.com

On-site secretariat opening hours:

Wednesday 24th April: 08:00-20:00
Thursday 25th April: 08:00-19:00
Friday 26th April: 08:00-19:00
Saturday 27th April: 08:00-13:00
A free wifi access is offered to all participants. Please connect to wifi_MC. A Wifi Lounge is available in room 101, level 1.

Wifi Lounge kindly sponsored by

---

**SOCIAL NETWORKS**
Follow us on Facebook @eadomelanoma

---

**Go to www.eadoparis2019.com**

to get the latest information, view the programme, abstracts, floor plan,...
PRACTICAL INFORMATION & VENUE FLOOR PLAN

LEVEL 1

AMPHITHEÂTRE LAVOISIER
PREVIEW ROOM
ROOM 151
EPOSTERS AREA
WIFI LOUNGE

LEVEL 0

EXHIBITION
BUSINESS SUITES
PETIT AMPHITHÉÂTRE
WELCOME AREA
VISIONARY SCIENCE IN IMMUNO-ONCOLOGY

Turning ideas into results
Cotellic (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties” of the officially published Summary of Product Characteristics).²

Combine COTELLIC™ with Zelboraf to achieve powerful efficacy in patients with BRAF V600(+) metastatic melanoma¹

Cotellic (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties” of the officially published Summary of Product Characteristics).²

Full Summary of Product Characteristics available at Roche booth

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 in the Summary of Product Characteristics for instructions on reporting side effects.

References

GUIDELINES FOR CHAIRS AND SPEAKERS

GUIDELINES FOR CHAIRPERSONS

• Locate your session room in due time
• Respect the timing allowed to the session and to each presentation
• All presentations, discussions and questions must be in English

A speakers’ preview room will be installed in room 131 on the 1st floor of the Maison de La Chimie [follow signage on site].

TECHNICAL REQUIREMENTS FOR ORAL PRESENTATIONS

The official language of the Congress is English, which means that all presentations and questions must be delivered in ENGLISH.

Presentations must be downloaded from a notebook in the preview room (follow signage onsite) as far in advance as possible and ONE HOUR BEFORE THE BEGINNING OF THE SESSION AT THE LATEST (presentations for early morning sessions should be handed over the evening before). Speakers are entirely responsible for the order, the loading and the pre-projection of their computer assisted presentation, using the equipment made available by the organisers.

Presentations received afterwords cannot be guaranteed audiovisual support. Personal computers cannot be connected to the projector in the sessions’ rooms. Every speaker has to go to the Preview room beforehand to provide his/her PowerPoint presentation.

In the sessions’ rooms speakers will be able to follow their presentations on a monitor at the lectern.

The opening hours of the PREVIEW ROOM during the Congress will be:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 24th April</td>
<td>from 08:00 to 19:00</td>
</tr>
<tr>
<td>Thursday 25th April</td>
<td>from 08:00 to 19:00</td>
</tr>
<tr>
<td>Friday 26th April</td>
<td>from 08:00 to 19:00</td>
</tr>
<tr>
<td>Saturday 27th April</td>
<td>from 08:00 to 13:00</td>
</tr>
</tbody>
</table>

All presentations will be considered as confidential by our staff and removed from the system at the end of the Congress.
ACKNOWLEDGMENT TO SPONSORS

The Organizing Committee warmly thanks the following companies for their support and contribution:

PLATINUM SPONSORS

- Bristol-Myers Squibb
- Novartis

GOLD SPONSORS

- MSD
- Pierre Fabre
- Roche
- Sanofi Genzyme
- Regeneron

SILVER SPONSOR

- Helsinn

BRONZE SPONSORS

- Amgen Oncology
- Merck
- Pfizer
SATELLITE SYMPOSIUM MSD: REDEFINING DISCUSSIONS IN THE MANAGEMENT OF MELANOMA PATIENTS

16:30 - 17:30 | AMPHITHEATRE LAVOISIER - Level 1

Chairs: Caroline ROBERT (France), Peter MOHR (Germany)

- Introduction
  Caroline ROBERT (France), Peter MOHR (Germany)
- How is long term survival in advanced melanoma shaping our practice?
  Helen GOGAS (Greece)
- Questions & answers and panel discussion
  Caroline ROBERT (France), Peter MOHR (Germany)
- How have recent advances in adjuvant treatment of melanoma altered the patient journey?
  Olivier MICHIELIN (Switzerland)
- Questions & answers and panel discussion
  Caroline ROBERT (France), Peter MOHR (Germany)
- Closing remarks
  Caroline ROBERT (France)

SATELLITE SYMPOSIUM BRISTOL-MYERS SQUIBB: PERSPECTIVES ON MELANOMA: PRESENT CHALLENGES AND FUTURE CONSIDERATIONS

13:00 - 14:00 | AMPHITHEATRE LAVOISIER - Level 1

Chairs: Caroline ROBERT (France)

- Welcome and introduction
  Caroline ROBERT (France)
- Expert insights into patient management
  Peter MOHR (Germany)
- Sequencing strategies in melanoma
  James LARKIN (United Kingdom)
- Immuno-oncology in melanoma: an interactive discussion
  Caroline ROBERT (France)
- Summary and close
  Caroline ROBERT (France)
**SATELLITE SYMPOSIUM NOVARTIS: TARGETED ADJUVANT THERAPY IN MELANOMA, COMBINING OUR KNOWLEDGE ON CURE-RATE MODELS AND TREATMENT-RELATED DECISIONS**

15:00 - 16:00 | PETIT AMPHITHEATRE - Level 0  
Chair: Céleste LEBBÉ (France)

- Welcome and introduction  
  Céleste LEBBÉ (France)
- Clinical evidence for targeted therapy of adjuvant melanoma patients and lessons from the cure-rate model  
  Axel HAUSCHILD (Germany)
- Beyond efficacy: What treatment-related factors should be considered?  
  Jean-Jacques GROB (France)
- Hot topics in adjuvant therapy – panel discussion and Q&A  
  Céleste LEBBÉ (France)
- Chair’s wrap-up and close  
  Céleste LEBBÉ (France)

**SATELLITE SYMPOSIUM HELSINN/RECORDATI RARE DISEASES: CHLORMETHINE GEL AND MF-CTCL: EXPLORING THE REAL-WORLD EVIDENCE**

18:00 - 19:00 | AMPHITHEATRE Lavoisier - Level 1  
Chair: Martine BAGOT (France), Ellen J. KIM (United States)

- Opening and welcome  
  Martine BAGOT (France)
- MF-CTCL management: the real-world evidence of chlormethine gel in North America (PROVe trial)  
  Ellen J. KIM (United States)
- A topical therapy for all stages? Real-world evidence of chlormethine gel in late-stage MF-CTCL  
  Martine BAGOT (France)
- Q&A session and closing: your views on chlormethine gel in early- and late-stage MF-CTCL  
  Ellen J. KIM (United States), Martine BAGOT (France)
FRIDAY 26TH APRIL

SATELLITE SYMPOSIUM PIERRE FABRE:
PATIENTS’ CASES IN THE EVOLVING LANDSCAPE OF BRAF-MUTANT METASTATIC MELANOMA

13:00 - 14:00 | AMPHITHEATRE LAVOISIER - Level 1

Chairs: Céleste LEBBÉ (France), Axel HAUSCHILD (Germany)

• Welcome and introductions
  Céleste LEBBÉ (France)

• Clinical trials Experience
  Paolo ASCIERTO (Italy)

• Real life clinical case with Encorafenib + Binimetinib
  Christoffer GEBHARDT (Germany)

• Discussion
  Céleste LEBBÉ (France), Axel HAUSCHILD (Germany), Paolo ASCIERTO (Italy), Christoffer GEBHARDT (Germany)

• Conclusions
  Axel HAUSCHILD (Germany)

SATELLITE SYMPOSIUM ROCHE: BUILDING ON EXPERIENCE:
OPTIMISING TREATMENT OUTCOMES FOR PATIENTS WITH ADVANCED BASAL CELL CARCINOMA

15:30 - 16:30 | PETIT AMPHITHEATRE - Level 0

Chair: Nicole BASSET-SEGUIN (France)

• Welcome and introduction
  Nicole BASSET-SEGUIN (France)

• Experience in the treatment of advanced BCC
  Nicole BASSET-SEGUIN (France)

• Managing patients with advanced BCC: interactive patient cases
  Dirk SCHADENDORF (Germany), Laurent MORTIER (France), Nicole BASSET-SEGUIN (France)

• Building on experience: optimising treatment outcomes
  Laurent MORTIER (France)

• Closing remarks
  Nicole BASSET-SEGUIN (France)
Welcome and Introduction
Céleste LEBBÉ (France)

Cases and Conversations of Immunotherapy in Advanced CSCC
Céleste LEBBÉ (France), Axel HAUSCHILD (Germany),
Michael MIGDEN (United States)

Q&A and Conclusions
Céleste LEBBÉ (France), Axel HAUSCHILD (Germany),
Michael MIGDEN (United States)
EXHIBITION FLOOR PLAN

List of exhibitors, company details, profiles and floor plan as per the date of printing 5th April 2019.

ACCESS TO WELCOME AREA AND OTHER MEETING ROOMS

ACCESS TO MAIN AUDITORIUM AND POSTER AREA

LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>n°</th>
</tr>
</thead>
<tbody>
<tr>
<td>3GEN INC./ DERMLITE</td>
<td>5</td>
</tr>
<tr>
<td>ALMIRALL</td>
<td>20</td>
</tr>
<tr>
<td>ALTRUIST DERMATOLOGIST SUNSCREEN</td>
<td>18</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>9</td>
</tr>
<tr>
<td>CANFIELD SCIENTIFIC GMBH</td>
<td>16</td>
</tr>
<tr>
<td>EADO (EUROPEAN ASSOCIATION OF DERMATO-ONCOLOGY)</td>
<td>19</td>
</tr>
<tr>
<td>F. HOFFMANN-LA ROCHE</td>
<td>10</td>
</tr>
<tr>
<td>HELSINN HEALTHCARE</td>
<td>14</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>n°</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGEA SPA</td>
<td>4</td>
</tr>
<tr>
<td>IMMUNOCORE</td>
<td>17</td>
</tr>
<tr>
<td>PIERRE FABRE</td>
<td>12/13</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>6/7</td>
</tr>
<tr>
<td>SANOFI GENZYMEN AND REGENERON</td>
<td>10bis</td>
</tr>
<tr>
<td>SPECLIPSE</td>
<td>3</td>
</tr>
<tr>
<td>SUN PHARMA</td>
<td>1/2</td>
</tr>
</tbody>
</table>
3GEN INC./ DERMLITE

Contact: John BOTTJER - 31521 Rancho Viejo Rd., #104 - 92675 San Juan Capistrano - United States of America
Phone: +1 (949) 481 6384 - Fax: +1 (949) 240 7492
E-mail: jb@3geninc.com - Web site: www.dermlite.com

3Gen manufacturers the DermLite brand of skin imaging devices.

ALMIRALL

Contact: Julien FEUGER - Ronda del General Mitre, 151- 08022 Barcelona - Spain
Phone: +34 932912807 - E-mail: julien.feuger@almirall.com
Web site: www.almirall.com

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations.

ALTRUIST DERMATOLOGIST SUNSCREEN

Contact: David WESTERBEEK VAN EERTEN - Unit 2, Bellingham Way, Aylesford - ME20 6SQ Kent - United Kingdom
Phone: +31 334 614 844 - E-mail: sunscreen@altruistsun.com
Web site: www.altruistsun.com

Altruist provides dermatologist specification sunscreen at the lowest possible price with the aim of reducing the incidence of skin cancer. Created by Dr Andrew Birnie, Consultant Dermatologist. 10p/product is given to people with albinism in Africa. Available through amazon.co.uk & amazon.es/it/de

BRISTOL-MYERS SQUIBB

Contact: Robert BAGUST - 3401 Princeton Pike - 08648 Lawrenceville - United States of America
Phone: +1 (800) 332 2056 - E-mail: Robert.Bagust@bms.com
Web site: www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
**CANFIELD SCIENTIFIC GMBH**  
Booth n°: 16  

**Contact:** Peter KLAR - Osningstr. 25 - 33605 Bielefeld - Germany  
**Phone:** +49 521 329856 0 - **Fax:** +49 521 329856 40  
**E-mail:** post.europe@canfieldsci.com - **Web site:** www.canfieldsci.com  

Canfield Scientific, Inc. is the global leader in developing and distributing industry-leading imaging and photographic systems for medical and aesthetic practices, hospitals, skin care and wellness centers, spas and medical spas.

**EADO (EUROPEAN ASSOCIATION OF DERMATO-ONCOLOGY)**  
Booth n°: 19  

**Contact:** Claus GARBE - Flughofstrasse 54 - 8152 Zurich-Glattburg - Switzerland  
**Phone:** +33 1 53 85 82 70 - **E-mail:** info@eado.org  
**Web site:** www.eado.org  

EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical.

**F. HOFFMANN-LA ROCHE**  
Booth n°: 10  

**Contact:** Michelle KOPPITSCH MCMANUS - Grenzacherstrasse 124 - CH-4070 Basel - Switzerland  
**Phone:** +41 799 090 211 - **E-mail:** michelle.koppitsch-mcmanus@roche.com  
**Web site:** www.roche.com  

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment.

**HELSINN HEALTHCARE**  
Booth n°: 14  

**Contact:** Sabrina PERUCCHI - Via Pian Scario 9 - 6912 Pazzallo - Switzerland  
**Phone:** +41 919 852 121 - **E-mail:** sabrina.perucchi@helsinn.com  
**Web site:** www.helsinn.com  

Helsinn, is a privately owned pharmaceutical group with a unique licensing business model and a robust portfolio of marketed cancer care products and development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients guided by core family values: respect, integrity, quality.
**IGEA SPA**

**Contact:** Claudio VOILA - Via Parmenide 10/a - 41012 Carpi - Italy  
**Phone:** +39 059 699 600 - **E-mail:** oncology@igeamedical.com  
**Web site:** www.igeamedical.com

IGEA improves patient’s Quality of Life developing and producing innovative, effective and safe therapeutic systems for clinical practice in Oncology. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies to treat tumour nodules to skin, subcutaneous tissue, parenchyma and bone.

**IMMUNOCORE**

**Contact:** Martina WITSEL - 101 Park Drive, Milton Park, Abingdon - OX14 4RY Oxford - United Kingdom  
**Phone:** +44 1235 438600 - **E-mail:** info@immunocore.com  
**Web site:** www.immunocore.com

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, working to create first-in-class biological therapies that have the potential to transform patients’ lives. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases.

**NOVARTIS**

**Contact:** George MARKOULIS - Largo U. Boccioni 1-21040 Origgio - Italy  
**Phone:** +39 348 3317991 - **E-mail:** george.markoulis@novartis.com  
**Web site:** www.novartis.com

Novartis Oncology is inspired by patients to revolutionize the research, development and manufacturing of innovative, high quality medicines that help to improve and extend people’s lives.

**PIERRE FABRE**

45, place Abel Gance - 92654 Boulogne Billancourt - France  
**Phone:** +33 1 49 10 80 00  
**Web site:** www.pierre-fabre.com

Pierre Fabre is a private French multinational, pharmaceutical and dermo-cosmetic company. It is 86%-owned by a foundation government-recognized of public-interest. Oncology is one of our priorities, with programs focusing particularly on targeted therapies, biotherapies and immuno-oncology.
SANOFI GENZYME AND REGENERON  

Contact: Valery OSIAS - 50 Binney Street - 02142 Cambridge, MA - United States of America  
Phone: +1508 240 4750 - E-mail: valery.osias@sanofi.com  

Sanofi Genzyme, a global healthcare leader, discovers and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi Genzyme.

SPECLIPSE  

Contact: Sung Hyun PYUN - 310 De Guigne Dr - 94085 Sunnyvale - United States of America  
Phone: +1 4 08328 2900 - E-mail: ceo@speclipse.com  
Web site: www.speclipse.com

Speclipse, Inc. has developed a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms. Clinical trials of Spectra-Scope in US and Australia have shown sensitivity of 95% and specificity of 87.

SUN PHARMA  

Contact: Tom HENDRIX - Polarisavenue 87 - 2132JH Hoofddorp - The netherlands  
Phone: +31 (0)23 568 5501 - Fax: +31 (0)23 568 5505  
E-mail: tom.hendrix@sunpharma.com - Web site: www.sunpharma.com

Within Sun Pharmaceuticals we focus on meeting the needs of patients & physicians. Our operations in Europe are supported by global R&D and manufacturing with an unwavering commitment to quality.

All company details and profiles included in the directory were provided by the exhibitors and it is their responsibility to ensure accuracy.
PATIENTS’ CASES IN THE EVOLVING LANDSCAPE OF BRAF-MUTANT METASTATIC MELANOMA
FRIDAY 26TH APRIL 13:00-14:00 - Amphithéâtre LAVOISIER

PROGRAMME

13.00 WELCOME AND INTRODUCTIONS
Céleste Lebbe

13.05 CLINICAL TRIALS EXPERIENCE
Paolo Ascierto
Moderator Céleste Lebbe

13.25 REAL LIFE CLINICAL CASE WITH ENCORAFENIB + BINIMETINIB
Christoffer Gebhardt
Moderator Axel Hauschild

13.45 DISCUSSION
Panel discussion

13.55 CONCLUSIONS
Axel Hauschild

CO-CHAIRS

CÉLESTE LEBBE
Paris, France

AXEL HAUSCHILD
Kiel, Germany

PAOLO ASCIERTO
Naples, Italy

CHRISTOFFER GEBHARDT
Hamburg, Germany

SPEAKERS
Erivedge (vismodegib) is indicated for the treatment of adult patients with symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.

Full Summary of Product Characteristics available at Roche booth


PR/ERIV/1903/0001a  Date of preparation: March 2019
Incyte est une société biopharmaceutique internationale dont la rigueur scientifique est placée au centre de la découverte, du développement et de la mise à disposition de médicaments innovants. Incyte s’engage à faire la différence dans la vie des patients avec des molécules qui permettront de répondre à des besoins médicaux majeurs non couverts en oncologie et dans d’autres pathologies.